Survival after TL therapy. PFS (A) and OS (B) after TL initiation for all patients receiving TL off-trial. Progression-free (C) and overall survival (D) stratified by L-MIND eligibility, excluding laboratory-based markers of renal, hepatic, and hematologic function. Tafa, tafasitamab.